tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Pharvaris Reports Q2 2025 Financials and Advances Phase 3 Studies

Story Highlights
Pharvaris Reports Q2 2025 Financials and Advances Phase 3 Studies

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Pharvaris ( (PHVS) ) has shared an announcement.

On August 12, 2025, Pharvaris reported its financial results for the second quarter of 2025 and provided a business update. The company announced progress in its pivotal Phase 3 studies for deucrictibant, aimed at treating and preventing HAE and AAE-C1INH attacks. The RAPIDe-3 study, focusing on on-demand treatment, is expected to yield topline results in the fourth quarter of 2025. Meanwhile, the CHAPTER-3 study continues enrollment with results anticipated in the second half of 2026. Pharvaris also plans to initiate the CREAATE study by the end of 2025. The company’s financial position is strong, bolstered by a recent $201 million public offering, extending its cash runway into the first half of 2027.

The most recent analyst rating on (PHVS) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.

Spark’s Take on PHVS Stock

According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.

Pharvaris exhibits significant financial difficulties, with no revenue and ongoing losses, resulting in a low financial performance score. Despite some technical momentum, the valuation is poor due to negative earnings. The stock’s overall score is affected by these financial and valuation challenges, despite its technical strength.

To see Spark’s full report on PHVS stock, click here.

More about Pharvaris

Pharvaris is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists. Their primary products target bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).

Average Trading Volume: 106,900

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.33B

For detailed information about PHVS stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1